Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 4187 | 877399-52-5 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 22.15 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.75 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.09 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 38.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 23, 2012 | EMA | ||
Aug. 26, 2011 | FDA | PF PRISM CV |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Disease progression | 801.68 | 24.30 | 379 | 8810 | 90921 | 46585952 |
Neoplasm progression | 728.15 | 24.30 | 251 | 8938 | 26432 | 46650441 |
Non-small cell lung cancer | 445.58 | 24.30 | 107 | 9082 | 3037 | 46673836 |
Lung neoplasm malignant | 411.41 | 24.30 | 143 | 9046 | 15346 | 46661527 |
Death | 324.78 | 24.30 | 362 | 8827 | 335186 | 46341687 |
Photopsia | 241.11 | 24.30 | 69 | 9120 | 3907 | 46672966 |
Visual impairment | 224.67 | 24.30 | 148 | 9041 | 66541 | 46610332 |
Nausea | 193.24 | 24.30 | 418 | 8771 | 687036 | 45989837 |
Vomiting | 124.75 | 24.30 | 274 | 8915 | 452520 | 46224353 |
Pleural effusion | 109.05 | 24.30 | 106 | 9083 | 82846 | 46594027 |
Dysgeusia | 103.61 | 24.30 | 76 | 9113 | 40415 | 46636458 |
Renal abscess | 101.75 | 24.30 | 24 | 9165 | 627 | 46676246 |
Constipation | 89.10 | 24.30 | 138 | 9051 | 173959 | 46502914 |
Oedema peripheral | 87.95 | 24.30 | 131 | 9058 | 159575 | 46517298 |
Oesophagitis | 87.44 | 24.30 | 46 | 9143 | 13605 | 46663268 |
Diarrhoea | 84.57 | 24.30 | 271 | 8918 | 559331 | 46117542 |
Vitreous floaters | 76.71 | 24.30 | 31 | 9158 | 5014 | 46671859 |
Pneumonitis | 65.22 | 24.30 | 50 | 9139 | 28370 | 46648503 |
Interstitial lung disease | 59.94 | 24.30 | 63 | 9126 | 53886 | 46622987 |
Neoplasm malignant | 57.58 | 24.30 | 43 | 9146 | 23456 | 46653417 |
Oedema | 50.37 | 24.30 | 64 | 9125 | 67007 | 46609866 |
Drug ineffective | 48.19 | 24.30 | 38 | 9151 | 677800 | 45999073 |
Lung adenocarcinoma | 41.39 | 24.30 | 19 | 9170 | 4185 | 46672688 |
Dysphagia | 39.03 | 24.30 | 61 | 9128 | 77251 | 46599622 |
Decreased appetite | 38.68 | 24.30 | 104 | 9085 | 193732 | 46483141 |
Non-small cell lung cancer metastatic | 38.49 | 24.30 | 11 | 9178 | 618 | 46676255 |
Embolism | 37.22 | 24.30 | 21 | 9168 | 7117 | 46669756 |
Multiple-drug resistance | 36.39 | 24.30 | 15 | 9174 | 2550 | 46674323 |
Transaminases increased | 35.51 | 24.30 | 35 | 9154 | 27726 | 46649147 |
Drug resistance | 34.34 | 24.30 | 28 | 9161 | 17340 | 46659533 |
Acquired gene mutation | 34.25 | 24.30 | 10 | 9179 | 606 | 46676267 |
Pericardial effusion | 34.16 | 24.30 | 33 | 9156 | 25510 | 46651363 |
Renal cyst | 33.24 | 24.30 | 21 | 9168 | 8738 | 46668135 |
Drug hypersensitivity | 31.78 | 24.30 | 5 | 9184 | 243820 | 46433053 |
Vision blurred | 31.03 | 24.30 | 56 | 9133 | 79652 | 46597221 |
Metastases to central nervous system | 30.80 | 24.30 | 22 | 9167 | 11199 | 46665674 |
Bradycardia | 30.29 | 24.30 | 50 | 9139 | 66248 | 46610625 |
Oesophageal pain | 29.85 | 24.30 | 13 | 9176 | 2530 | 46674343 |
Visual brightness | 29.63 | 24.30 | 5 | 9184 | 20 | 46676853 |
Hepatotoxicity | 29.18 | 24.30 | 30 | 9159 | 24979 | 46651894 |
Pulmonary embolism | 27.67 | 24.30 | 64 | 9125 | 108521 | 46568352 |
Oesophageal ulcer | 27.22 | 24.30 | 14 | 9175 | 3947 | 46672926 |
Bronchial carcinoma | 24.90 | 24.30 | 8 | 9181 | 669 | 46676204 |
Alanine aminotransferase increased | 24.61 | 24.30 | 54 | 9135 | 88397 | 46588476 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Disease progression | 765.21 | 26.09 | 368 | 6468 | 79506 | 29866136 |
Neoplasm progression | 579.85 | 26.09 | 199 | 6637 | 17824 | 29927818 |
Non-small cell lung cancer | 416.75 | 26.09 | 108 | 6728 | 3622 | 29942020 |
Death | 346.83 | 26.09 | 413 | 6423 | 356870 | 29588772 |
Lung neoplasm malignant | 299.57 | 26.09 | 117 | 6719 | 15015 | 29930627 |
Visual impairment | 113.12 | 26.09 | 76 | 6760 | 30362 | 29915280 |
Nausea | 84.40 | 26.09 | 199 | 6637 | 296758 | 29648884 |
Neoplasm malignant | 72.24 | 26.09 | 47 | 6789 | 17767 | 29927875 |
Oedema peripheral | 62.40 | 26.09 | 97 | 6739 | 105735 | 29839907 |
Photopsia | 58.08 | 26.09 | 20 | 6816 | 1786 | 29943856 |
Interstitial lung disease | 53.11 | 26.09 | 67 | 6769 | 60130 | 29885512 |
Lung adenocarcinoma | 51.62 | 26.09 | 23 | 6813 | 4076 | 29941566 |
Diarrhoea | 48.21 | 26.09 | 176 | 6660 | 333927 | 29611715 |
Drug ineffective | 45.51 | 26.09 | 11 | 6825 | 340376 | 29605266 |
Constipation | 44.90 | 26.09 | 87 | 6749 | 112819 | 29832823 |
Dysgeusia | 43.96 | 26.09 | 40 | 6796 | 24761 | 29920881 |
Oesophagitis | 41.69 | 26.09 | 28 | 6808 | 11143 | 29934499 |
Pneumonitis | 38.65 | 26.09 | 39 | 6797 | 27415 | 29918227 |
Oedema | 38.12 | 26.09 | 48 | 6788 | 42945 | 29902697 |
Lung adenocarcinoma stage IV | 38.07 | 26.09 | 8 | 6828 | 103 | 29945539 |
Vomiting | 32.57 | 26.09 | 117 | 6719 | 219701 | 29725941 |
Pleural effusion | 31.78 | 26.09 | 59 | 6777 | 74007 | 29871635 |
Hypoalbuminaemia | 30.32 | 26.09 | 23 | 6813 | 11069 | 29934573 |
Second primary malignancy | 28.80 | 26.09 | 18 | 6818 | 6338 | 29939304 |
Non-small cell lung cancer stage IV | 28.01 | 26.09 | 7 | 6829 | 201 | 29945441 |
Decreased appetite | 26.76 | 26.09 | 85 | 6751 | 149825 | 29795817 |
Metastases to central nervous system | 26.56 | 26.09 | 18 | 6818 | 7266 | 29938376 |
Source | Code | Description |
---|---|---|
ATC | L01ED01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Anaplastic lymphoma kinase (ALK) inhibitors |
FDA MoA | N0000020000 | Receptor Tyrosine Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
FDA MoA | N0000182139 | Cytochrome P450 2B6 Inhibitors |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
FDA MoA | N0000187061 | Organic Cation Transporter 2 Inhibitors |
FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
FDA MoA | N0000191265 | Organic Cation Transporter 1 Inhibitors |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:59163 | biological marker |
CHEBI has role | CHEBI:62434 | alk inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.74 | Basic |
pKa2 | 6.14 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
200MG | XALKORI | PF PRISM CV | N202570 | Aug. 26, 2011 | RX | CAPSULE | ORAL | March 11, 2023 | TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE. |
250MG | XALKORI | PF PRISM CV | N202570 | Aug. 26, 2011 | RX | CAPSULE | ORAL | March 11, 2023 | TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE. |
200MG | XALKORI | PF PRISM CV | N202570 | Aug. 26, 2011 | RX | CAPSULE | ORAL | Jan. 14, 2024 | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
250MG | XALKORI | PF PRISM CV | N202570 | Aug. 26, 2011 | RX | CAPSULE | ORAL | Jan. 14, 2024 | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
200MG | XALKORI | PF PRISM CV | N202570 | Aug. 26, 2011 | RX | CAPSULE | ORAL | Jan. 14, 2028 | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
250MG | XALKORI | PF PRISM CV | N202570 | Aug. 26, 2011 | RX | CAPSULE | ORAL | Jan. 14, 2028 | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
ALK tyrosine kinase receptor | Kinase | INHIBITOR | Ki | 9.13 | CHEMBL | CHEMBL | |||
Hepatocyte growth factor receptor | Kinase | INHIBITOR | Kd | 9.26 | CHEMBL | CHEMBL | |||
SRSF protein kinase 1 | Kinase | Kd | 5.74 | CHEMBL | |||||
Receptor-type tyrosine-protein kinase FLT3 | Kinase | Kd | 6.68 | CHEMBL | |||||
Cyclin-dependent kinase-like 2 | Kinase | Kd | 5.68 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | Kd | 8 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | Kd | 5.57 | CHEMBL | |||||
Serine/threonine-protein kinase DCLK1 | Kinase | Kd | 6.48 | CHEMBL | |||||
Muscle, skeletal receptor tyrosine-protein kinase | Kinase | Kd | 6.64 | CHEMBL | |||||
Vascular endothelial growth factor receptor 1 | Kinase | Kd | 5.64 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | Kd | 6.25 | CHEMBL | |||||
Fibroblast growth factor receptor 3 | Kinase | Kd | 5.57 | CHEMBL | |||||
Serine/threonine-protein kinase 35 | Kinase | Kd | 6.21 | CHEMBL | |||||
Insulin receptor | Kinase | AGONIST | Kd | 6.47 | CHEMBL | ||||
Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Kinase | Kd | 5.40 | CHEMBL | |||||
Serine/threonine-protein kinase RIO3 | Kinase | Kd | 5.40 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 3 | Kinase | Kd | 5.48 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 6.05 | CHEMBL | |||||
Ephrin type-B receptor 4 | Kinase | Kd | 6.24 | CHEMBL | |||||
Tyrosine-protein kinase JAK2 | Kinase | Kd | 6.54 | CHEMBL | |||||
Serine/threonine-protein kinase NIM1 | Kinase | Kd | 5.34 | CHEMBL | |||||
Serine/threonine-protein kinase SBK1 | Kinase | Kd | 5.89 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 15 | Kinase | Kd | 5.55 | CHEMBL | |||||
Aurora kinase A | Kinase | Kd | 6.59 | CHEMBL | |||||
Tyrosine-protein kinase JAK1 | Kinase | Kd | 6.48 | CHEMBL | |||||
Tyrosine-protein kinase ITK/TSK | Kinase | Kd | 5.70 | CHEMBL | |||||
Tyrosine-protein kinase SYK | Kinase | Kd | 5.60 | CHEMBL | |||||
Interferon-induced, double-stranded RNA-activated protein kinase | Kinase | Kd | 5.96 | CHEMBL | |||||
Tyrosine-protein kinase BTK | Kinase | Kd | 5.11 | CHEMBL | |||||
Cyclin-dependent kinase 11B | Kinase | Kd | 6.12 | CHEMBL | |||||
Serine/threonine-protein kinase D1 | Kinase | Kd | 6 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 13 | Kinase | Kd | 6.64 | CHEMBL | |||||
Serine/threonine-protein kinase TBK1 | Kinase | Kd | 6.16 | CHEMBL | |||||
Ephrin type-A receptor 1 | Kinase | Kd | 6.85 | CHEMBL | |||||
Serine/threonine-protein kinase Nek7 | Kinase | Kd | 5.24 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 1 | Kinase | Kd | 7.41 | CHEMBL | |||||
AarF domain-containing protein kinase 4 | Kinase | Kd | 5.96 | CHEMBL | |||||
Tyrosine-protein kinase Fgr | Kinase | Kd | 6.17 | CHEMBL | |||||
Serine/threonine-protein kinase D3 | Kinase | Kd | 6.29 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 7 | Kinase | Kd | 5.74 | CHEMBL | |||||
Tyrosine-protein kinase FRK | Kinase | Kd | 5.54 | CHEMBL | |||||
Ephrin type-A receptor 8 | Kinase | Kd | 6.55 | CHEMBL | |||||
Serine/threonine-protein kinase 10 | Kinase | Kd | 7.36 | CHEMBL | |||||
Tyrosine-protein kinase Fer | Kinase | Kd | 6.57 | CHEMBL | |||||
Serine/threonine-protein kinase PLK4 | Kinase | Kd | 7.22 | CHEMBL | |||||
AP2-associated protein kinase 1 | Kinase | Kd | 5.64 | CHEMBL | |||||
Tyrosine-protein kinase JAK3 | Kinase | Kd | 6.70 | CHEMBL | |||||
Tyrosine-protein kinase Yes | Kinase | Kd | 6.11 | CHEMBL | |||||
Serine/threonine-protein kinase TAO1 | Kinase | Kd | 5.92 | CHEMBL | |||||
Serine/threonine-protein kinase TNNI3K | Kinase | Kd | 6.96 | CHEMBL | |||||
Aurora kinase C | Kinase | Kd | 5.37 | CHEMBL | |||||
High affinity nerve growth factor receptor | Kinase | Kd | 7.02 | CHEMBL | |||||
Rho-associated protein kinase 1 | Kinase | Kd | 5.43 | CHEMBL | |||||
Ankyrin repeat and protein kinase domain-containing protein 1 | Kinase | Kd | 6.11 | CHEMBL | |||||
Homeodomain-interacting protein kinase 4 | Kinase | Kd | 5.44 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 5 | Kinase | Kd | 7.10 | CHEMBL | |||||
Serine/threonine-protein kinase DCLK2 | Kinase | Kd | 6.43 | CHEMBL | |||||
Misshapen-like kinase 1 | Kinase | Kd | 5.36 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 4 | Kinase | Kd | 5.44 | CHEMBL | |||||
Insulin receptor-related protein | Kinase | Kd | 6.22 | CHEMBL | |||||
Mast/stem cell growth factor receptor Kit | Kinase | Kd | 6.10 | CHEMBL | |||||
BMP-2-inducible protein kinase | Kinase | Kd | 6.13 | CHEMBL | |||||
Insulin-like growth factor 1 receptor | Kinase | Kd | 6.11 | CHEMBL | |||||
Ephrin type-A receptor 6 | Kinase | Kd | 7.19 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase kinase 2 | Kinase | Kd | 5.82 | CHEMBL | |||||
Aurora kinase B | Kinase | Kd | 7.12 | CHEMBL | |||||
STE20-like serine/threonine-protein kinase | Kinase | Kd | 7.74 | CHEMBL | |||||
Bone morphogenetic protein receptor type-1B | Kinase | Kd | 6.64 | CHEMBL | |||||
Macrophage-stimulating protein receptor | Kinase | Kd | 7.60 | CHEMBL | |||||
Non-receptor tyrosine-protein kinase TYK2 | Kinase | Kd | 6.68 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 1 | Kinase | Kd | 7.31 | CHEMBL | |||||
Serine/threonine-protein kinase 4 | Kinase | Kd | 6.24 | CHEMBL | |||||
Ephrin type-A receptor 7 | Kinase | Kd | 6.33 | CHEMBL | |||||
Serine/threonine-protein kinase 3 | Kinase | Kd | 6 | CHEMBL | |||||
Inhibitor of nuclear factor kappa-B kinase subunit beta | Kinase | Kd | 5.26 | CHEMBL | |||||
Serine/threonine-protein kinase Nek9 | Kinase | Kd | 6.10 | CHEMBL | |||||
Serine/threonine-protein kinase TAO2 | Kinase | Kd | 6.05 | CHEMBL | |||||
Tyrosine-protein kinase Lyn | Kinase | Kd | 6.03 | CHEMBL | |||||
5'-AMP-activated protein kinase catalytic subunit alpha-1 | Kinase | Kd | 5.62 | CHEMBL | |||||
Cytoplasmic tyrosine-protein kinase BMX | Kinase | Kd | 5.44 | CHEMBL | |||||
Ephrin type-A receptor 5 | Kinase | Kd | 6 | CHEMBL | |||||
LIM domain kinase 1 | Kinase | Kd | 6.08 | CHEMBL | |||||
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | Kinase | IC50 | 7.29 | CHEMBL | |||||
Serine/threonine-protein kinase ULK2 | Kinase | Kd | 5.80 | CHEMBL | |||||
Ephrin type-A receptor 4 | Kinase | Kd | 6.44 | CHEMBL | |||||
Ephrin type-B receptor 1 | Kinase | Kd | 6.92 | CHEMBL | |||||
Activated CDC42 kinase 1 | Kinase | Kd | 6.12 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 3 | Kinase | Kd | 7.12 | CHEMBL | |||||
Dual specificity testis-specific protein kinase 1 | Kinase | Kd | 6.42 | CHEMBL | |||||
Focal adhesion kinase 1 | Kinase | Kd | 6.51 | CHEMBL | |||||
NT-3 growth factor receptor | Kinase | Kd | 7.09 | CHEMBL | |||||
Tyrosine-protein kinase ZAP-70 | Kinase | Kd | 5.38 | CHEMBL | |||||
Activin receptor type-1 | Kinase | Kd | 6.36 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 3 | Kinase | Kd | 7.51 | CHEMBL | |||||
G protein-coupled receptor kinase 4 | Kinase | Kd | 5.38 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 2 | Kinase | Kd | 7.14 | CHEMBL | |||||
Serine/threonine-protein kinase ULK3 | Kinase | Kd | 5.17 | CHEMBL | |||||
Abelson tyrosine-protein kinase 2 | Kinase | Kd | 6.34 | CHEMBL | |||||
Serine/threonine-protein kinase 26 | Kinase | Kd | 5.55 | CHEMBL | |||||
Protein-tyrosine kinase 2-beta | Kinase | Kd | 6.72 | CHEMBL | |||||
Tyrosine-protein kinase Blk | Kinase | Kd | 6.96 | CHEMBL | |||||
Angiopoietin-1 receptor | Kinase | Kd | 6.57 | CHEMBL | |||||
Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Kinase | Kd | 6.15 | CHEMBL | |||||
Peripheral plasma membrane protein CASK | Kinase | Kd | 6.85 | CHEMBL | |||||
Dual serine/threonine and tyrosine protein kinase | Kinase | Kd | 6.35 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase ROS | Kinase | Kd | 8.39 | CHEMBL | |||||
Ephrin type-B receptor 6 | Kinase | Kd | 8.22 | CHEMBL | |||||
Serine/threonine-protein kinase SIK2 | Kinase | Kd | 6.70 | CHEMBL | |||||
Serine/threonine-protein kinase TAO3 | Kinase | Kd | 6.31 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 1 | Kinase | Kd | 5.96 | CHEMBL | |||||
Cyclin-dependent kinase 7 | Kinase | Kd | 6.48 | CHEMBL | |||||
Rho-associated protein kinase 2 | Kinase | Kd | 5.48 | CHEMBL | |||||
Tyrosine-protein kinase Fyn | Kinase | Kd | 5.89 | CHEMBL | |||||
Macrophage colony-stimulating factor 1 receptor | Kinase | Kd | 6.68 | CHEMBL | |||||
Uncharacterized serine/threonine-protein kinase SBK3 | Kinase | Kd | 6.62 | CHEMBL | |||||
Activin receptor type-1B | Kinase | Kd | 6.07 | CHEMBL | |||||
Tyrosine-protein kinase receptor Tie-1 | Kinase | Kd | 6.96 | CHEMBL | |||||
TGF-beta receptor type-1 | Kinase | Kd | 6 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | Kd | 5.89 | CHEMBL | |||||
Myotonin-protein kinase | Kinase | Kd | 5.85 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 6.29 | CHEMBL | |||||
Tyrosine-protein kinase receptor TYRO3 | Kinase | Kd | 6.10 | CHEMBL | |||||
Tyrosine-protein kinase Fes/Fps | Kinase | Kd | 6.35 | CHEMBL | |||||
Tyrosine-protein kinase Lck | Kinase | Kd | 7.52 | CHEMBL | |||||
Leukocyte tyrosine kinase receptor | Kinase | Kd | 7.92 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 19 | Kinase | Kd | 6.01 | CHEMBL | |||||
Tyrosine-protein kinase receptor UFO | Kinase | Kd | 8.11 | CHEMBL | |||||
BDNF/NT-3 growth factors receptor | Kinase | Kd | 7.43 | CHEMBL | |||||
NUAK family SNF1-like kinase 2 | Kinase | Kd | 6.92 | CHEMBL | |||||
SRSF protein kinase 3 | Kinase | Kd | 5.09 | CHEMBL | |||||
Tyrosine-protein kinase TXK | Kinase | Kd | 6.07 | CHEMBL | |||||
LIM domain kinase 2 | Kinase | Kd | 6.16 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 12 | Kinase | Kd | 6.77 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 1 | Kinase | Kd | 5.80 | CHEMBL | |||||
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha | Kinase | Kd | 5.49 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 3 | Kinase | Kd | 6.96 | CHEMBL | |||||
Cyclin-dependent kinase 11A | Kinase | Kd | 6.38 | CHEMBL | |||||
Serine/threonine-protein kinase RIO1 | Kinase | Kd | 5.21 | CHEMBL | |||||
Ribosomal protein S6 kinase beta-1 | Kinase | Kd | 6.19 | CHEMBL | |||||
Serine/threonine-protein kinase ULK1 | Kinase | Kd | 6 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 4 | Kinase | Kd | 5.68 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 7.10 | CHEMBL | |||||
Tyrosine-protein kinase Mer | Kinase | Kd | 8.44 | CHEMBL | |||||
Mitogen-activated protein kinase 7 | Kinase | Kd | 6.29 | CHEMBL | |||||
Ephrin type-A receptor 2 | Kinase | Kd | 7 | CHEMBL | |||||
Non-receptor tyrosine-protein kinase TNK1 | Kinase | Kd | 6.49 | CHEMBL | |||||
Ephrin type-A receptor 3 | Kinase | Kd | 6.15 | CHEMBL | |||||
Angiopoietin-1 receptor | Kinase | IC50 | 6.35 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | IC50 | 5.94 | CHEMBL | |||||
Macrophage-stimulating protein receptor | Kinase | IC50 | 7.10 | CHEMBL |
ID | Source |
---|---|
4030983 | VUID |
N0000183253 | NUI |
D09731 | KEGG_DRUG |
4030983 | VANDF |
C2974289 | UMLSCUI |
CHEBI:64310 | CHEBI |
VGH | PDB_CHEM_ID |
CHEMBL601719 | ChEMBL_ID |
DB08865 | DRUGBANK_ID |
D000077547 | MESH_DESCRIPTOR_UI |
11626560 | PUBCHEM_CID |
4903 | IUPHAR_LIGAND_ID |
9301 | INN_ID |
53AH36668S | UNII |
1148495 | RXNORM |
185331 | MMSL |
28080 | MMSL |
d07800 | MMSL |
013917 | NDDF |
703637000 | SNOMEDCT_US |
703638005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Xalkori | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-8140 | CAPSULE | 250 mg | ORAL | NDA | 32 sections |
Xalkori | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-8141 | CAPSULE | 200 mg | ORAL | NDA | 32 sections |